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Autism spectrum disorders (ASD) are highly heritable, yet genetically heterogeneous neu-
rodevelopmental conditions. Recent genome-wide association and gene expression stud-
ies have provided evidence supporting the notion that the large number of genetic variants
associated with ASD converge toward a core set of dysregulated biological processes.
Here we review recent data demonstrating the involvement of synaptic dysfunction and
abnormal immune responses in ASD, and discuss the functional interplay between the two
phenomena.
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INTRODUCTION
Autism spectrum disorders (ASD) are a spectrum of neurode-
velopmental conditions characterized by language deficits, social
impairments, and repetitive behaviors (Abrahams and Geschwind,
2008). Typically the disorder is diagnosed around 2–3 years of
age and manifests with a regression in acquired language and
behavioral skills. However, there are wide variations in the clinical
presentation and disease progression. In addition to variable sever-
ity of the core symptomatology, ASD patients also present with a
variable mix of co-morbid conditions: epilepsy, gastro-intestinal
problems, intellectual disability, anxiety, and depression (Kim and
Lord, 2013). Mirroring its clinical heterogeneity,ASD is also genet-
ically very heterogeneous (State and Levitt, 2011). Based on the
results of genome-wide association (GWAS) studies, candidate
gene re-sequencing, and exome-sequencing studies, it is currently
estimated that hundreds of genetic variants, including common
and rare genetic variants, contribute to the disease (Murdoch and
State, 2013). What are the molecular pathways that mediate the
phenotypic expression of this myriad of genetic variants into
a recognizable triad of symptoms? Here we review recent stud-
ies demonstrating a convergence of ASD genetic changes toward
two main biological processes: synaptic function and immune
responses, and discuss their functional interplay, with a focus on
immune modulation of neuronal synapses (Figure 1).
FROMMANY GENES TO COMMON BIOLOGICAL PROCESSES
Results from genome-wide studies are beginning to confirm the
long-held hypothesis that the wide variety of genetic variants
associated with ASD ultimately converge on a core set of mol-
ecular pathways (Murdoch and State, 2013). It is worth noting
that pathway enrichment analyses are inherently limited by our
current knowledge of signaling pathways and molecular interac-
tions, and thus the identification of distinct pathways by different
studies might partially reflect yet uncharacterized complexity of
molecular pathways.
Four recent studies undertook exome-sequencing in several
hundreds of parent-child trios in order to identify de novo sin-
gle nucleotide variants (SNVs) and copy number variants (CNVs)
associated with the disease (Iossifov et al., 2012; Neale et al., 2012;
O’Roak et al., 2012; Sanders et al., 2012). The study by O’Roak et
al. found that the most disruptive de novo mutations converged
onto a highly interconnected beta-catenin/chromatin remodeling
protein network, which is involved in neuronal differentiation and
synaptic formation (Ille and Sommer, 2005). Iossifov et al. found
an enrichment of de novo variants in genes encoding proteins
associated with the fragile X syndrome protein, FMRP, suggest-
ing an involvement in synaptic plasticity. The study by Neale et al.
demonstrated that genes carrying functional de novo variants were
functionally related to each other and to synaptic genes previously
implicated in ASD. Using a network-based analysis of genetic asso-
ciation data, Talkowski et al. (2012) showed that rare de novo CNVs
occurring in ASD cases affect primarily genes related to synapse
development, axon targeting, and neuron motility. Collectively,
these studies highlighted the fact that genes containing pathogenic
DNA sequence variants in ASD patients affected primarily genes
involved in various aspects of synaptic function.
While genetic association studies identify genetic loci poten-
tially implicated in the disease, they do not assess the functional
consequences of the associated variants. On the other hand, tran-
scriptome analyses comparing disease and control groups assess
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FIGURE 1 | Interactions between synaptic function and immune
molecules and cells, and possible mechanisms leading toASD. Multiple
aspects of synaptic function (blue boxes) are regulated by astrocytes,
microglia, and immune molecules (yellow boxes). Either immune activation
during neuroinflammation or impaired resting state activity of immune cells
in the brain could impair synaptic function and lead to ASD.
gene function (by quantifying mRNA output), but are liable
to environmental variations in gene expression, and functional
changes unrelated to the disease. Thus ideally, functional genomic
studies should simultaneously assess DNA sequence variation and
gene expression, in a disease-relevant tissue. However, the scarce
availability of post-mortem brain tissue from ASD cases limits the
sample size of such studies below appropriate statistical power.
Attempting to address this problem, we performed a genome-wide
assessment of gene expression in multiple brain regions (frontal
cortex, temporal cortex, and cerebellum) from 19 autism cases
and 17 unaffected controls, and integrated these results with pre-
vious ASD GWAS data (Wang et al., 2009). Using a network-based
approach for the analysis of gene expression data we identified
two modules of co-expressed genes dysregulated in a large sub-
set of ASD cases (Voineagu et al., 2011). One of these modules
was downregulated in ASD brain and was enriched for neu-
ronal genes involved in synaptic function. A second module was
upregulated in ASD brain and contained primarily genes func-
tioning in immune and inflammatory responses. To integrate the
gene expression results with previously published GWAS data, we
performed a pathway enrichment analysis of ASD GWAS data
using the two co-expression modules as pre-defined “pathways.”
We found that the neuronal genes downregulated in ASD, but
not the immune/inflammatory genes, showed an enrichment for
genetic association, as measured by a large ASD GWAS study
(Wang et al., 2009). These results supported the heritability of
synaptic gene dysfunction in ASD and suggested that the upregula-
tion of immune and inflammatory genes is likely environmentally
mediated or secondary to the synaptic dysfunction.
Although gene expression analyses of ASD brain are just begin-
ning to emerge, several studies have evaluated gene expression in
readily available peripheral tissues (blood and lymphoblast cell
lines) from ASD patients (Hu et al., 2006, 2009; Gregg et al., 2008;
Enstrom et al., 2009). A common result of these studies was the
demonstration of increased expression of immune and inflam-
matory genes in ASD. Moreover, a comparison of gene expression
studies of peripheral tissues in idiopathic autism and related neu-
rodevelopmental disorders showed a convergence of gene expres-
sion abnormalities on genes involved in immune responses (Lintas
et al., 2012). Interestingly, an analysis of genetic variants nominally
associated with ASD found that these variants were enriched in
brain expression quantitative trait loci (brain eQTLs), but not lym-
phoblast eQTLs (Davis et al., 2012). Thus gene expression studies
collectively support the concept that (a) immune and inflamma-
tory genes are upregulated in ASD, a phenomenon observed both
in the brain and in peripheral tissues, and (b) neuronal synaptic
genes are downregulated in ASD brains.
The involvement of synaptic dysfunction and immune
responses in ASD had been demonstrated by multiple approaches
(Betancur et al., 2009; Pizzarelli and Cherubini, 2011; Wright and
Washbourne, 2011; Grabrucker, 2012; Onore et al., 2012; Zoghbi
and Bear, 2012; Ebert and Greenberg, 2013), but it was not until
large-scale genomic studies that these biological processes could
be regarded as points of convergence of the heterogeneous genetic
variants underlying ASD.
INTERPLAY BETWEEN BRAIN IMMUNE PROCESSES AND
SYNAPTIC FUNCTION
Microglia, the main resident immune cells in the brain, have been
long believed to be active only in response to immune insults, and
to exist in a “resting state” in the normal brain. However, this view
has dramatically changed over the last decade, and it is becom-
ing increasingly clear that immune cells and molecules play an
active role in the normal brain function. Microglia are believed
to populate the CNS in the non-vascularized embryonic period
and to originate from progenitors from the yolk sac. It has also
been proposed that a second wave of microglia, originating from
blood monocytes, may populate the CNS during the early postna-
tal period, a period particularly important for neurodevelopment
(Davis and Carson, 2013). Microglia actively survey the brain
parenchyma, constantly extending their processes to survey their
microenvironment every few hours (Nimmerjahn et al., 2005).
Importantly, microglia are required for synaptic pruning during
postnatal neurodevelopment (Paolicelli et al., 2011). A recent study
(Schafer et al., 2012) demonstrated that microglial synaptic prun-
ing is developmentally regulated and depends on neuronal activity.
This process was shown to be mediated by the complement recep-
tor (CR3) pathway, and inhibiting CR3 signaling led to sustained
deficits in synaptic connectivity.
Thus immune cells could affect neuronal synaptic function
either as a result of their activation during immune responses, or
due to a failure of their non-immune roles in the brain (Figure 1).
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Recent evidence supports the potential involvement of both of
these mechanisms in ASD pathogenesis.
Active neuroinflammation has been consistently demonstrated
in ASD brains. Prominent activation of microglia (Vargas et al.,
2005; Morgan et al., 2010), as well as increased levels of inflamma-
tory cytokines and chemokines [interferon-gamma, IL-1β, IL-6,
tumor necrosis factor (TNF)-α] have been documented in post-
mortem brain tissue and cerebrospinal fluid from ASD patients
(Onore et al., 2012). Recently, activated microglia have also been
observed by positron emission tomography in ASD subjects in sev-
eral brain regions (Suzuki et al., 2013). While it is not clear what
is the cause of microglial activation in ASD brain, the cytokines
produced by activated microglia have been demonstrated to affect
neuronal synaptic function (Onore et al., 2012). TNF-α regulates
neuronal cell proliferation and synaptic pruning (Cacci et al.,
2005), and modulates synaptic scaling (i.e., the adjustment of
synaptic strength for all synapses on a neuronal cell in response to
prolonged changes in electrical activity) (Stellwagen and Malenka,
2006). IL-1β regulates long-term potentiation and alters synaptic
plasticity (Schneider et al., 1998), while IL-6 has been implicated
in behavioral changes associated with maternal immune activa-
tion (Patterson, 2009). Mounting evidence suggests that mater-
nal immune activation, particularly during the first and second
trimester of pregnancy, may be an important environmental factor
in ASD (Onore et al., 2012). Rodent models of maternal immune
activation exhibit ASD-like behavioral changes (Patterson, 2009),
and the behavioral effects observed in offspring after maternal
immune activation appear to be mediated by microglia and IL-
6 (Hsiao and Patterson, 2011). In some mouse models increased
levels of IL-6 have been sufficient to induce behavioral changes
(Onore et al., 2012). Unlike peripheral macrophages, microglia
are long-lived, and thus it has been hypothesized that they could
maintain an “immunological memory” of an early immune insult,
leading to long-term neuronal deficits (Davis and Carson, 2013).
One of the first studies to demonstrate a direct causal rela-
tionship between microglial function and a behavioral phe-
notype, was a mouse model of obsessive-compulsive disorder
(Chen et al., 2010). HOXB8 encodes a homeobox transcrip-
tion factor expressed in the brain exclusively in bone-marrow-
derived microglia. HOXB8-null mice exhibit excessive patho-
logical grooming behavior similar to the obsessive-compulsive
symptoms of trichotillomania. Chen et al. demonstrated that nor-
mal bone marrow transplant could rescue the excessive grooming
and hair removal phenotype in the HOXB8 mutant mouse, and
that selective disruption of HOXB8 in the hematopoietic lineage
recapitulates pathological grooming. More recently, a role for non-
immune functions of microglia has also been demonstrated in
Rett syndrome, a pervasive developmental disorder, belonging
to the wider group of ASD. Rett syndrome is caused by loss of
function of the methyl-CpG binding protein 2 (MECP2) and is
characterized by an initial period of normal development of about
5 months followed by deceleration of language development, psy-
chomotor retardation, seizures and loss of social engagement skills
(Chahrour and Zoghbi, 2007). It was initially believed that Rett
syndrome is primarily due to loss of MECP2 function in neurons.
However several recent studies clearly demonstrated that MECP2
loss in glial cells impairs neuronal function and contributes to
the Rett syndrome symptomatology. MECP2 deficiency in astro-
cytes leads to impaired BDNF regulation, cytokine production,
and neuronal dendritic arborization (Maezawa et al., 2009). More-
over, MECP2-deficient astrocytes are unable to support normal
dendritic ramification of wild-type neurons (Ballas et al., 2009).
Remarkably, astrocyte-specific expression of MECP2 in a MECP2-
null mouse restored the normal neuronal dendritic morphol-
ogy, improved locomotion, anxiety, and respiratory abnormalities
(Lioy et al., 2011). A recent study by Derecki et al. (2012) demon-
strated that not only astrocytes but also microglia contribute to the
Rett syndrome phenotype. Using irradiation-mediated immune
ablation in MECP2-null mice, followed by wild-type bone mar-
row transplantation, this study demonstrated that the wild-type
microglia could arrest disease development. In addition, targeted
expression of MECP2 in myeloid cells ameliorated the pheno-
type in MECP2-null mice. These results implicated microglia
as important players in the pathophysiology of Rett syndrome,
and suggested a potential therapeutic benefit of bone marrow
transplantation in Rett syndrome.
CONCLUSION AND FUTURE DIRECTIONS
Understanding the core biological processes underlying the clinical
and genetic heterogeneity of ASD is as yet in incipient stages. Fur-
ther advances in elucidating the molecular underpinnings of ASD
are expected to result from (a) larger cohort sizes of GWAS and
exome-sequencing studies, (b) increased availability of archived
post-mortem brain tissue for transcriptome studies, and (c) inte-
grative analyses of genomic, transcriptomic, and epigenomic data.
At the same time, understanding the role of immune cells
in regulating synaptic function is also a newly developing field.
As discussed above, accumulating evidence supports the notion
that immune cells play important roles in normal brain func-
tion, outside of neuroinflammation. Of particular relevance to
ASD is the role of microglia in synaptic pruning during postna-
tal brain development, a period that coincides with the onset of
ASD symptoms. While it has been demonstrated that increased
numbers of activated microglia are present in brain parenchyma
of ASD patients (Vargas et al., 2005; Morgan et al., 2010; Suzuki
et al., 2013), these studies have not captured the early postna-
tal development window. Future studies, facilitated by early ASD
diagnosis, could shed further light on microglial activation occurs
during postnatal brain development and on potential changes in
the magnitude of this phenomenon across development and adult
life in ASD. Notably, abnormal synaptic density, which could result
from a deficit of synaptic pruning, is a feature of several ASD ani-
mal models [e.g., increased synaptic density in Fmr1 KO mice,
and decreased synaptic density in Rett syndrome mouse models
(Delorme et al., 2013)], but it remains to be demonstrated whether
it is also a feature of idiopathic ASD in human brain.
Since microglia and astrocytes have been shown to play a role
in synaptic formation and maturation, and mutations in neuronal
cell adhesion molecules have been associated with ASD, it is also
tempting to speculate that ASD neurons might be particularly
vulnerable to immune cell dysfunction in the brain.
Given the large amount of data supporting the role of immune
responses in ASD and other neuropsychiatric disorders, advances
in deciphering the functional interplay between immune cells and
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neuronal synaptic function will likely provide vital insights into
the mechanisms and potential therapy of neurodevelopmental
disorders.
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